AZD2171 in Treating Patients With Recurrent Small Cell Lung Cancer

NCT00245063 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

NIH

Sponsor class

Conditions

Recurrent Non-small Cell Lung Cancer

Interventions

DRUG: cediranib maleate
OTHER: laboratory biomarker analysis
OTHER: pharmacogenomic studies

Sponsor

National Cancer Institute (NCI)